Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059681) titled 'TecPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Teclistamab in the Real World (Japan)' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Relapsed or refractory multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - 1.To characterize teclistamab treatment strategies and administration models, including patient profiles, teclistamab's place in the treatment armamentarium... among Japanese healthcare providers for their patients with RRMM being treate...